Genoway risk profile
38 Normal where most of the sector sits
Measured 1 September 2026 from ALGEN's filed statements. Recomputed nightly.
38 (Normal), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 55 | Elevated | Stable | One-year price volatility — 42.8% |
| Operating pressure | 46 | Elevated | Worsening | Costs outgrowing revenue — +3.2 percentage points |
| Cash conversion | 100 | Acute | Worsening | Capital spending against operating cash — -7.66x |
| Leverage and coverage | 23 | Normal | Worsening | Net debt to EBITDA — 2.66x |
| Competitive position | 18 | Contained | Stable | Revenue-growth gap against peers — +7.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.